Chemed (CHE) Stock Forecast, Price Target & Predictions
CHE Stock Forecast
Chemed stock forecast is as follows: an average price target of $633.00 (represents a 15.65% upside from CHE’s last price of $547.34) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
CHE Price Target
The average price target for Chemed (CHE) is $633.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $633.00 to $633.00. This represents a potential 15.65% upside from CHE's last price of $547.34.
CHE Analyst Ratings
According to 1 Wall Street analysts, Chemed's rating consensus is 'Buy'. The analyst rating breakdown for CHE stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Chemed Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 05, 2024 | Frank Morgan | RBC Capital | $633.00 | $534.41 | 18.45% | 15.65% |
| May 21, 2024 | Frank Morgan | RBC Capital | $697.00 | $564.34 | 23.51% | 27.34% |
| Apr 28, 2022 | - | RBC Capital | $592.00 | $492.25 | 20.27% | 8.16% |
The latest Chemed stock forecast, released on Nov 05, 2024 by Frank Morgan from RBC Capital, set a price target of $633.00, which represents a 18.45% increase from the stock price at the time of the forecast ($534.41), and a 15.65% increase from CHE last price ($547.34).
Chemed Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 2 |
| Avg Price Target | $633.00 | $633.00 | $665.00 |
| Last Closing Price | $547.34 | $547.34 | $547.34 |
| Upside/Downside | 15.65% | 15.65% | 21.50% |
In the current month, the average price target of Chemed stock is $633.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 15.65% increase as opposed to Chemed's last price of $547.34. This month's average price target is down 0.00% compared to last quarter, and down -4.81% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 21, 2024 | RBC Capital | Outperform | Outperform | Hold |
| May 01, 2023 | RBC Capital | Outperform | Outperform | Hold |
| Apr 28, 2022 | RBC Capital | Outperform | Outperform | Hold |
Chemed's last stock rating was published by RBC Capital on May 21, 2024. The company gave CHE a "Outperform" rating, the same as its previous rate.
Chemed Financial Forecast
Chemed Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $564.53M | $553.82M | $560.16M | $546.65M | $526.47M | $531.29M | $530.55M | $540.98M | $538.67M | $532.26M | $527.36M | $533.29M | $528.30M | $502.20M | $515.80M | $522.32M | $480.61M | $473.58M | $462.03M | $439.18M | $405.86M |
| Avg Forecast | $666.02M | $649.25M | $640.72M | $636.19M | $636.10M | $612.22M | $599.20M | $591.46M | $586.64M | $558.42M | $562.54M | $548.78M | $546.60M | $527.05M | $538.07M | $538.57M | $543.18M | $531.87M | $511.85M | $510.26M | $537.20M | $514.22M | $522.90M | $523.04M | $524.20M | $478.89M | $471.72M | $468.28M | $381.07M | $399.21M |
| High Forecast | $671.85M | $654.94M | $646.34M | $641.76M | $641.67M | $614.20M | $599.20M | $591.46M | $591.78M | $558.42M | $567.47M | $553.59M | $551.39M | $527.05M | $538.07M | $538.57M | $543.18M | $531.87M | $511.85M | $510.26M | $537.20M | $514.22M | $522.90M | $523.04M | $524.20M | $478.89M | $471.72M | $468.28M | $457.28M | $479.05M |
| Low Forecast | $660.75M | $644.12M | $635.66M | $631.16M | $631.07M | $610.23M | $599.20M | $591.46M | $582.00M | $558.42M | $558.09M | $544.44M | $542.28M | $527.05M | $538.07M | $538.57M | $543.18M | $531.87M | $511.85M | $510.26M | $537.20M | $514.22M | $522.90M | $523.04M | $524.20M | $478.89M | $471.72M | $468.28M | $304.86M | $319.37M |
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 13 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.01% | 0.98% | 1.02% | 1.00% | 1.00% | 0.99% | 0.99% | 1.00% | 1.01% | 1.04% | 1.03% | 0.99% | 1.03% | 0.96% | 0.99% | 1.00% | 1.00% | 1.00% | 0.99% | 1.15% | 1.02% |
Chemed's average Quarter revenue forecast for Dec 23 based on 2 analysts is $586.64M, with a low forecast of $582.00M, and a high forecast of $591.78M. CHE's average Quarter revenue forecast represents a 3.92% increase compared to the company's last Quarter revenue of $564.53M (Sep 23).
Chemed EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 13 |
| EBITDA | - | - | - | - | - | - | - | - | - | $109.09M | $86.26M | $90.03M | $98.61M | $92.42M | $102.24M | $96.23M | $111.00M | $110.30M | $91.61M | $98.27M | $160.54M | $96.21M | $114.42M | $83.76M | $94.82M | $78.55M | $75.83M | $62.14M | $66.71M | $52.86M |
| Avg Forecast | $124.43M | $121.30M | $119.71M | $118.86M | $118.84M | $114.38M | $111.95M | $112.53M | $109.60M | $104.33M | $105.10M | $102.30M | $118.02M | $98.47M | $100.53M | $93.00M | $101.48M | $99.37M | $95.63M | $88.00M | $100.37M | $96.07M | $97.69M | $83.07M | $97.94M | $89.47M | $88.13M | $62.98M | $56.53M | $51.97M |
| High Forecast | $125.52M | $122.36M | $120.76M | $119.90M | $119.88M | $114.75M | $111.95M | $135.03M | $110.56M | $104.33M | $106.02M | $122.76M | $141.62M | $98.47M | $100.53M | $111.60M | $101.48M | $99.37M | $95.63M | $105.60M | $100.37M | $96.07M | $97.69M | $99.69M | $97.94M | $89.47M | $88.13M | $75.58M | $67.84M | $62.36M |
| Low Forecast | $123.45M | $120.34M | $118.76M | $117.92M | $117.90M | $114.01M | $111.95M | $90.02M | $108.74M | $104.33M | $104.27M | $81.84M | $94.41M | $98.47M | $100.53M | $74.40M | $101.48M | $99.37M | $95.63M | $70.40M | $100.37M | $96.07M | $97.69M | $66.46M | $97.94M | $89.47M | $88.13M | $50.38M | $45.23M | $41.58M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.05% | 0.82% | 0.88% | 0.84% | 0.94% | 1.02% | 1.03% | 1.09% | 1.11% | 0.96% | 1.12% | 1.60% | 1.00% | 1.17% | 1.01% | 0.97% | 0.88% | 0.86% | 0.99% | 1.18% | 1.02% |
2 analysts predict CHE's average Quarter EBITDA for Dec 23 to be $109.60M, with a high of $110.56M and a low of $108.74M. This is 0.47% upper than Chemed's previous annual EBITDA (Sep 23) of $109.09M.
Chemed Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 13 |
| Net Income | - | - | - | - | - | - | - | - | - | $74.96M | $53.38M | $54.12M | $62.13M | $56.87M | $66.46M | $64.17M | $74.63M | $72.00M | $56.52M | $65.40M | $113.75M | $67.72M | $82.10M | $55.89M | $65.58M | $58.95M | $50.73M | $44.67M | $45.00M | $29.84M |
| Avg Forecast | $110.10M | $91.35M | $88.38M | $83.86M | $102.31M | $85.14M | $84.36M | $72.09M | $94.26M | $73.90M | $76.72M | $65.53M | $79.34M | $70.87M | $72.85M | $59.58M | $77.42M | $68.48M | $65.38M | $58.57M | $78.24M | $60.60M | $57.24M | $55.43M | $62.38M | $50.52M | $47.51M | $45.27M | $38.13M | $29.34M |
| High Forecast | $111.35M | $92.39M | $89.39M | $84.81M | $103.06M | $86.38M | $84.36M | $86.50M | $95.34M | $74.74M | $77.59M | $78.64M | $95.21M | $70.87M | $72.85M | $71.49M | $77.42M | $68.48M | $65.38M | $70.28M | $78.24M | $60.60M | $57.24M | $66.52M | $62.38M | $50.52M | $47.51M | $54.32M | $45.76M | $35.21M |
| Low Forecast | $108.97M | $90.41M | $87.47M | $82.99M | $101.55M | $83.89M | $84.36M | $57.67M | $94.11M | $73.14M | $75.93M | $52.43M | $63.47M | $70.87M | $72.85M | $47.66M | $77.42M | $68.48M | $65.38M | $46.85M | $78.24M | $60.60M | $57.24M | $44.35M | $62.38M | $50.52M | $47.51M | $36.22M | $30.51M | $23.48M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.01% | 0.70% | 0.83% | 0.78% | 0.80% | 0.91% | 1.08% | 0.96% | 1.05% | 0.86% | 1.12% | 1.45% | 1.12% | 1.43% | 1.01% | 1.05% | 1.17% | 1.07% | 0.99% | 1.18% | 1.02% |
Chemed's average Quarter net income forecast for Dec 23 is $94.26M, with a range of $94.11M to $95.34M. CHE's average Quarter net income forecast represents a 25.75% increase compared to the company's last Quarter net income of $74.96M (Sep 23).
Chemed SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 13 |
| SG&A | - | - | - | - | - | - | - | - | - | $95.34M | $94.99M | $97.58M | $96.93M | $83.99M | $87.85M | $93.89M | $92.07M | $89.22M | $90.18M | $88.56M | $86.81M | $88.32M | $84.51M | $70.58M | $83.29M | $76.84M | $71.56M | $74.03M | $69.00M | $69.46M |
| Avg Forecast | $110.62M | $107.83M | $106.42M | $105.66M | $105.65M | $101.68M | $99.52M | $101.05M | $97.43M | $92.75M | $93.43M | $91.87M | $97.89M | $87.54M | $89.37M | $83.51M | $90.22M | $88.34M | $85.01M | $79.31M | $89.22M | $85.40M | $86.85M | $70.00M | $87.06M | $79.54M | $78.35M | $75.03M | $58.47M | $68.29M |
| High Forecast | $111.59M | $108.78M | $107.35M | $106.59M | $106.57M | $102.01M | $99.52M | $121.26M | $98.29M | $92.75M | $94.25M | $110.24M | $117.47M | $87.54M | $89.37M | $100.22M | $90.22M | $88.34M | $85.01M | $95.17M | $89.22M | $85.40M | $86.85M | $84.00M | $87.06M | $79.54M | $78.35M | $90.04M | $70.17M | $81.95M |
| Low Forecast | $109.74M | $106.98M | $105.57M | $104.83M | $104.81M | $101.35M | $99.52M | $80.84M | $96.66M | $92.75M | $92.69M | $73.49M | $78.31M | $87.54M | $89.37M | $66.81M | $90.22M | $88.34M | $85.01M | $63.45M | $89.22M | $85.40M | $86.85M | $56.00M | $87.06M | $79.54M | $78.35M | $60.02M | $46.78M | $54.64M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.03% | 1.02% | 1.06% | 0.99% | 0.96% | 0.98% | 1.12% | 1.02% | 1.01% | 1.06% | 1.12% | 0.97% | 1.03% | 0.97% | 1.01% | 0.96% | 0.97% | 0.91% | 0.99% | 1.18% | 1.02% |
Chemed's average Quarter SG&A projection for Dec 23 is $97.43M, based on 2 Wall Street analysts, with a range of $96.66M to $98.29M. The forecast indicates a 2.19% rise compared to CHE last annual SG&A of $95.34M (Sep 23).
Chemed EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 13 |
| EPS | - | - | - | - | - | - | - | - | - | $4.97 | $3.54 | $3.62 | $4.17 | $3.82 | $4.45 | $4.28 | $4.89 | $4.62 | $3.57 | $4.08 | $7.12 | $4.25 | $5.16 | $3.50 | $4.09 | $3.69 | $3.18 | $2.80 | $2.79 | $1.84 |
| Avg Forecast | $7.30 | $6.06 | $5.86 | $5.56 | $6.78 | $5.64 | $5.59 | $5.48 | $6.25 | $4.90 | $5.09 | $4.81 | $5.31 | $4.65 | $4.78 | $4.47 | $5.08 | $4.49 | $4.29 | $4.02 | $5.13 | $3.97 | $3.75 | $3.65 | $4.09 | $3.31 | $3.12 | $2.96 | $2.00 | $1.76 |
| High Forecast | $7.38 | $6.13 | $5.93 | $5.62 | $6.83 | $5.73 | $5.59 | $5.54 | $6.32 | $4.96 | $5.14 | $4.86 | $5.37 | $4.65 | $4.78 | $4.47 | $5.08 | $4.49 | $4.29 | $4.02 | $5.13 | $3.97 | $3.75 | $3.65 | $4.09 | $3.31 | $3.12 | $2.96 | $2.40 | $2.11 |
| Low Forecast | $7.22 | $5.99 | $5.80 | $5.50 | $6.73 | $5.56 | $5.59 | $5.42 | $6.24 | $4.85 | $5.03 | $4.76 | $5.26 | $4.65 | $4.78 | $4.47 | $5.08 | $4.49 | $4.29 | $4.02 | $5.13 | $3.97 | $3.75 | $3.65 | $4.09 | $3.31 | $3.12 | $2.96 | $1.60 | $1.41 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.01% | 0.70% | 0.75% | 0.78% | 0.82% | 0.93% | 0.96% | 0.96% | 1.03% | 0.83% | 1.01% | 1.39% | 1.07% | 1.37% | 0.96% | 1.00% | 1.11% | 1.02% | 0.95% | 1.40% | 1.05% |
According to 2 Wall Street analysts, Chemed's projected average Quarter EPS for Dec 23 is $6.25, with a low estimate of $6.24 and a high estimate of $6.32. This represents a 25.75% increase compared to CHE previous annual EPS of $4.97 (Sep 23).
Chemed Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ACHC | Acadia Healthcare Company | $37.09 | $82.33 | 121.97% | Buy |
| SGRY | Surgery Partners | $22.75 | $40.80 | 79.34% | Buy |
| HCSG | Healthcare Services Group | $11.36 | $17.33 | 52.55% | Hold |
| INNV | InnovAge | $4.78 | $6.80 | 42.26% | Hold |
| EHAB | Enhabit | $7.27 | $10.25 | 40.99% | Hold |
| CHE | Chemed | $547.34 | $633.00 | 15.65% | Buy |
| ADUS | Addus HomeCare | $120.20 | $132.80 | 10.48% | Buy |
| PNTG | Pennant Group | $31.81 | $34.67 | 8.99% | Buy |
| SEM | Select Medical | $37.01 | $40.00 | 8.08% | Buy |
| UHS | Universal Health Services | $196.79 | $208.47 | 5.94% | Hold |
| ENSG | Ensign Group | $144.56 | $148.20 | 2.52% | Buy |
| EHC | Encompass Health | $99.10 | $97.00 | -2.12% | Buy |